Materialise NV (MTLS) Q1 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 24 2025
0mins
Should l Buy MTLS?
Source: SeekingAlpha
Total Revenue €66.4 million, an increase of more than 4% year-over-year.
EBIT €0.6 million, down from €2.7 million year-over-year.
Net Result Loss of €0.5 million or €0.01 per share, compared to a profit of €3.6 million in Q1 2024.
Net Cash Position €67.7 million, an increase of almost €7 million compared to the beginning of the quarter.
Adjusted EBIT €0.6 million, down from €2.7 million year-over-year, representing an adjusted EBIT margin of 1%.
Adjusted EBITDA €6.1 million, down from €8.1 million year-over-year, representing an adjusted EBITDA margin of 9.3%.
Gross Profit Margin 55.3%, down from 56.5% in Q1 2024.
R&D Expenses Increased by €2.4 million or 6.9% year-over-year, with more than €11 million spent on R&D.
Cash Flow from Operating Activities Almost €10 million for the first quarter.
Free Cash Flow €8 million for the quarter.
Deferred Revenue Increased by €1.9 million, totaling almost €49 million.
Manufacturing Revenue Change Decreased by 5.5% year-over-year.
Medical Revenue Change Increased by almost 19% year-over-year.
Software Revenue Change Decreased by around 6% year-over-year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MTLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MTLS
About MTLS
Materialise NV is a Belgium-based company that is engaged in the software industry. The Company is a provider of software and three-dimensional (3D) printing services that incorporates 3D printing experience into a wide range of software solutions and 3D printing services. It transforms businesses with three elements of align: quality, reliability, and repeatability through which it forms the backbone of the 3D printing industry. The solutions are built 3D printing applications in several industries, including healthcare, automotive, aerospace, art and design, and consumer goods. It also operates in the domestic market and worldwide, including Colombia, Brazil, Australia, Malaysia, China, Japan, Austria, Poland, Germany, and France, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Materialise Reports Q1 2026 Earnings Highlights
- Financial Performance: Materialise reported a GAAP EPS of €0.03 for Q1 2026, with revenue at €66.28M, reflecting a slight decline of 0.2% year-over-year, indicating competitive pressures in the market while maintaining a stable revenue base.
- Adjusted EBIT Growth: The adjusted EBIT surged to €2,470k from €646k in Q1 2025, demonstrating significant progress in cost management and execution discipline, thereby enhancing profitability.
- Cash Flow and Buybacks: Driven by positive free cash flow, the net cash position increased by €2,021k over the quarter to €72,826k, with €2,308k invested in share buybacks, reflecting strong cash generation capabilities.
- Full-Year Guidance Reaffirmed: The company reaffirmed its revenue guidance for fiscal year 2026 in the range of €273M to €283M and maintained its adjusted EBIT guidance of €10,000k to €12,000k, showcasing confidence in future growth and ongoing strategic execution focus.
See More
Materialise Sets 2026 Revenue Target Amid Earnings Announcement
- Earnings Announcement: Materialise is set to release its Q1 earnings on May 7 before market open, with consensus EPS estimate at $0.01 and revenue estimate at $78.5 million, reflecting a 9.3% year-over-year growth potential in the medical sector.
- Earnings Forecast Adjustments: Over the past three months, EPS estimates have seen no upward revisions and one downward revision, while revenue estimates also faced one downward adjustment, indicating market caution regarding the company's short-term performance.
- Medical Segment Growth: Materialise outlines a revenue target of €273 million to €283 million for 2026, maintaining double-digit growth in its medical segment, which highlights the effectiveness of the company's strategic investments in the healthcare market.
- Financial Performance Beats Expectations: In its latest earnings report, Materialise achieved a GAAP EPS of $0.12 and revenue of $82.44 million, exceeding market expectations by $420,000, showcasing a robust recovery in both software and medical sectors.
See More
Materialise to Release Q1 2026 Financial Results
- Earnings Release Schedule: Materialise NV will announce its financial results for Q1 2026 on May 7, 2026, at 1:00 a.m. ET, providing critical financial data to assess the company's performance.
- Management Conference Call: On the same day, senior management will hold a conference call at 8:30 a.m. ET to discuss the Q1 financial results, aiming to provide investors and analysts with in-depth performance analysis and future outlook.
- Webcast Access: Investors can access the audio webcast of the conference call through the company’s website, ensuring transparent information dissemination, while the call will be archived for later review, enhancing information accessibility.
- Company Background: Materialise boasts over 30 years of 3D printing experience, offering a range of software solutions and services aimed at driving innovation across healthcare, automotive, aerospace, and other industries, showcasing its leadership in the global 3D printing sector.
See More
Materialise to Release Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Materialise NV will announce its financial results for Q1 2026 on May 7 at 1:00 a.m. ET, reflecting the company's commitment to transparency and timely information disclosure.
- Management Conference Call: Senior management will hold a conference call on the same day at 8:30 a.m. ET to discuss the Q1 financial results, aiming to enhance investor understanding and confidence in the company's performance.
- Webcast Availability: The conference call will be accessible via a live audio webcast on the company's website, ensuring global investors can receive real-time information and fostering better engagement between the company and its investors.
- Industry Leadership: As a global leader in 3D-printed medical devices and software, Materialise's innovation and technological expertise will lay a strong foundation for its future financial performance, attracting increased investor interest.
See More
Materialise Transfers RapidFit Business to Management Team
- Increased Business Independence: Materialise's decision to transfer the RapidFit business to its management team allows it to operate as an independent company, enhancing market flexibility and customer focus, with the transaction expected to close around April 30, 2026.
- Core Business Focus: This move aligns with Materialise's growth strategy by concentrating investments and resources on the most promising business lines while enabling RapidFit to leverage its core strengths to drive global growth.
- Technological Advantage Utilization: RapidFit specializes in delivering custom 3D-printed jigs and quality control solutions for the automotive and manufacturing sectors, utilizing advanced additive manufacturing technologies to improve production efficiency, reduce lead times, and support quality assurance processes.
- Stable Customer Impact: The transaction is not expected to affect existing customer orders or ongoing projects, ensuring that RapidFit can maintain continuity in customer service after becoming independent.
See More
Materialise NV Q4 2025 Earnings Call Highlights
- Dual Listing Advantage: Materialise NV completed its dual listing on Euronext Brussels, which, while not raising capital, broadens its European investor base and enhances operational flexibility, potentially paving the way for future ADS or share buyback initiatives.
- Share Buyback Implementation: The company announced a share buyback program of up to EUR 30 million, having already repurchased 187,500 shares for nearly USD 1 million, demonstrating a commitment to shareholder value and market confidence.
- Medical Business Growth: The Medical segment treated over 17,000 patients in 2025, surpassing a cumulative total of 700,000 patients, with expectations for continued double-digit growth, solidifying its position as a key growth driver for the company.
- Strong Financial Performance: In Q4 2025, revenue grew by 6.8% year-on-year to EUR 70.2 million, with a gross profit margin of 58.1% and adjusted EBIT of EUR 4 million, reflecting ongoing improvements in cost control and profitability.
See More
Materialise Reports Q1 2026 Earnings Highlights
- Financial Performance: Materialise reported a GAAP EPS of €0.03 for Q1 2026, with revenue at €66.28M, reflecting a slight decline of 0.2% year-over-year, indicating competitive pressures in the market while maintaining a stable revenue base.
- Adjusted EBIT Growth: The adjusted EBIT surged to €2,470k from €646k in Q1 2025, demonstrating significant progress in cost management and execution discipline, thereby enhancing profitability.
- Cash Flow and Buybacks: Driven by positive free cash flow, the net cash position increased by €2,021k over the quarter to €72,826k, with €2,308k invested in share buybacks, reflecting strong cash generation capabilities.
- Full-Year Guidance Reaffirmed: The company reaffirmed its revenue guidance for fiscal year 2026 in the range of €273M to €283M and maintained its adjusted EBIT guidance of €10,000k to €12,000k, showcasing confidence in future growth and ongoing strategic execution focus.
See More
Materialise Sets 2026 Revenue Target Amid Earnings Announcement
- Earnings Announcement: Materialise is set to release its Q1 earnings on May 7 before market open, with consensus EPS estimate at $0.01 and revenue estimate at $78.5 million, reflecting a 9.3% year-over-year growth potential in the medical sector.
- Earnings Forecast Adjustments: Over the past three months, EPS estimates have seen no upward revisions and one downward revision, while revenue estimates also faced one downward adjustment, indicating market caution regarding the company's short-term performance.
- Medical Segment Growth: Materialise outlines a revenue target of €273 million to €283 million for 2026, maintaining double-digit growth in its medical segment, which highlights the effectiveness of the company's strategic investments in the healthcare market.
- Financial Performance Beats Expectations: In its latest earnings report, Materialise achieved a GAAP EPS of $0.12 and revenue of $82.44 million, exceeding market expectations by $420,000, showcasing a robust recovery in both software and medical sectors.
See More
Materialise to Release Q1 2026 Financial Results
- Earnings Release Schedule: Materialise NV will announce its financial results for Q1 2026 on May 7, 2026, at 1:00 a.m. ET, providing critical financial data to assess the company's performance.
- Management Conference Call: On the same day, senior management will hold a conference call at 8:30 a.m. ET to discuss the Q1 financial results, aiming to provide investors and analysts with in-depth performance analysis and future outlook.
- Webcast Access: Investors can access the audio webcast of the conference call through the company’s website, ensuring transparent information dissemination, while the call will be archived for later review, enhancing information accessibility.
- Company Background: Materialise boasts over 30 years of 3D printing experience, offering a range of software solutions and services aimed at driving innovation across healthcare, automotive, aerospace, and other industries, showcasing its leadership in the global 3D printing sector.
See More
Materialise to Release Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Materialise NV will announce its financial results for Q1 2026 on May 7 at 1:00 a.m. ET, reflecting the company's commitment to transparency and timely information disclosure.
- Management Conference Call: Senior management will hold a conference call on the same day at 8:30 a.m. ET to discuss the Q1 financial results, aiming to enhance investor understanding and confidence in the company's performance.
- Webcast Availability: The conference call will be accessible via a live audio webcast on the company's website, ensuring global investors can receive real-time information and fostering better engagement between the company and its investors.
- Industry Leadership: As a global leader in 3D-printed medical devices and software, Materialise's innovation and technological expertise will lay a strong foundation for its future financial performance, attracting increased investor interest.
See More
Materialise Transfers RapidFit Business to Management Team
- Increased Business Independence: Materialise's decision to transfer the RapidFit business to its management team allows it to operate as an independent company, enhancing market flexibility and customer focus, with the transaction expected to close around April 30, 2026.
- Core Business Focus: This move aligns with Materialise's growth strategy by concentrating investments and resources on the most promising business lines while enabling RapidFit to leverage its core strengths to drive global growth.
- Technological Advantage Utilization: RapidFit specializes in delivering custom 3D-printed jigs and quality control solutions for the automotive and manufacturing sectors, utilizing advanced additive manufacturing technologies to improve production efficiency, reduce lead times, and support quality assurance processes.
- Stable Customer Impact: The transaction is not expected to affect existing customer orders or ongoing projects, ensuring that RapidFit can maintain continuity in customer service after becoming independent.
See More
Materialise NV Q4 2025 Earnings Call Highlights
- Dual Listing Advantage: Materialise NV completed its dual listing on Euronext Brussels, which, while not raising capital, broadens its European investor base and enhances operational flexibility, potentially paving the way for future ADS or share buyback initiatives.
- Share Buyback Implementation: The company announced a share buyback program of up to EUR 30 million, having already repurchased 187,500 shares for nearly USD 1 million, demonstrating a commitment to shareholder value and market confidence.
- Medical Business Growth: The Medical segment treated over 17,000 patients in 2025, surpassing a cumulative total of 700,000 patients, with expectations for continued double-digit growth, solidifying its position as a key growth driver for the company.
- Strong Financial Performance: In Q4 2025, revenue grew by 6.8% year-on-year to EUR 70.2 million, with a gross profit margin of 58.1% and adjusted EBIT of EUR 4 million, reflecting ongoing improvements in cost control and profitability.
See More
